

S1 Table. Subsequent treatment after atezolizumab plus chemotherapy

Subsequent treatment	RW-ACE (n=100)
Line of treatment (No. of patients)	
Second	52
Third	20
≥ Fourth	6
Treatment type (No. of treatments)	
Chemotherapy/non-anthracycline	71
Camptothecin analogues	44
Paclitaxel	25
Platinum-etoposide doublet	2
Chemotherapy/anthracycline	7

RW-ACE, real-world atezolizumab/carboplatin/etoposide study.